Pivotal Point Tracking Personalis (PSNL): Expanded Medicare Coverage for "NeXT Personal" Opens Gigantic US Sales Market

Personalis is a pioneer in precision oncology, offering ultra-sensitive gene sequencing for cancer monitoring. On May 13, the stock reacted with a significant price jump to the news of the expanded Medicare coverage for the "NeXT Personal" test for immunotherapy monitoring in solid tumors. Shortly before, the biotech company had already impressed with Q1 revenues of $15.47 million. Partners include leading biopharma companies and clinics that rely on Personalis platforms for early tumor detection. The company benefits massively from state cost...